Senior Executives

Dr. Rohmann received his medical degree from the University of Mainz, Germany; his Ph.D. in medicine from the Erasmus University in Rotterdam, the Netherlands; and an Executive MBA from the Kellogg School of Management in the USA. Sven brings more than three decades of experience as a successful executive in the industry, recently as acting CEO for Oasmia Pharmaceuticals, as founding CEO at Ganymed Pharmaceuticals, and senior management roles at Novartis and Merck KGaA.

Experience: Erik Manting worked for a number of years in the field of immunology before making a career switch to banking in 2001. He spent the next 15 years in different commercial and management roles and his last five years in banking as Executive Director Corporate Finance at Kempen & Co, an investment bank with a focus on Life Sciences & Healthcare. He joined DCprime in 2017, first as business development consultant, and from March 2018 as CEO until the combination with Immunicum in December 2020.

Ongoing engagements: Supervisory board member Synerkine Pharma BV, Independent Director Transcode Therapeutics Inc.

Experience: Jeroen Rovers trained as a pharmaceutical physician at the European Center of Pharmaceutical Medicine in Basel. In the past 20 years he worked in different academic institutes and companies, such as Wyeth and Organon and most recently at Kiadis Pharma where he held the role as Chief Medical Officer. Most of the products he worked on are related to oncology, haematology and transplantation. He joined DCprime as Chief Medical Officer in 2018 and is Managing Director of DCprime after the merger with Immunicum in December 2020.

Experience: Alex Karlsson-Parra, MD, PhD has over 20 years of experience within transplantation immunology. In addition to his position as Co-Founder and CSO at Immunicum, he also serves as Associate Professor in Clinical Immunology at Uppsala University, Uppsala, Sweden, with special expertise in transplantation immunology and cancer immunotherapy and is former chairman of the Swedish Expert Group for Clinical immunology. Dr. Karlsson-Parra was awarded the Athena Prize, the Swedish healthcare´s most prestigious award for clinical research, in 2014. Prior to his current positions, he served as Associate Professor and Senior Physician at the Department of Clinical Immunology at Sahlgrenska University Hospital, Gothenburg, Sweden and Uppsala University Hospital, Sweden.

Ongoing engagements: –

Past engagements during the last five (5) years: Board member of Immunicum.

Experience: Sijme Zeilemaker joins Immunicum having most recently served as Director Business Development at InteRNA Technologies where he supported the preclinical oncology company in connecting with pharmaceutical and biotechnology companies, licensing technologies and exploring grant opportunities. Sijme also served as Head of Business for 2-BBB Medicines and Business Development Manager for to-BBB technologies where he provided partnering support and attracted funding.

Ongoing engagements: –

Past engagements during the last five (5) years: –

Experience: Peter Hein has extensive experience from leading positions in the life science industry. He served as CFO at Q-Med, Biolipox (Orexo) and BioArctic AB. He has also been CEO and CFO for the retail chain Granngården. Peter Hein also brings experience in management and finance from Ericsson and Swedish Match.

Ongoing engagements: Savelend Credit Group, Lacolle AB

Past engagements during the last five (5) years: Genovis AB

Experience: Peter has held a number of global development positions in the pharmaceutical industry including Senior Medical Scientist Haemat/Oncology Late Phase Development at Amgen (UK), Medical Director Early Clinical Development at GSK Bio (Cancer Immunotherapeutics, BE)), Global Oncology Lead at Glenmark Pharma (Immunotherapeutics, UK), Chief Medical Officer at Immunicum AB and Vice-President Global Clinical Development at AgenTus Therapeutics (BE). He is a board-certified medical doctor in Gastroenterology, qualified in Digestive Oncology and has a PhD in Medical Sciences from Leuven University, Belgium. He completed a post-doc at McGill University Health Center, Canada, and at Institut Gustave Roussy, France, and was on staff as Clinical Head Digestive Oncology at the University Hospital Antwerp before joining the pharmaceutical industry.

Ongoing engagements:  SparkClin BV (consultancy company, BE), co-founder and managing director since 23 Jan 2020 and Medical Advisor to AgenTus Therapeutics Inc., Lexington (MA), USA since 05/2020

Experience: Sharon Longhurst has over 15 years in leading CMC efforts in small and medium sized organization. Sharon Longhurst joins Immunicum from her previous position as Senior CMC Manager at Akari Therapeutics, where she was responsible for all aspects of CMC, including clinical supply and distribution. Prior to that, Sharon spent 5 years as Principal Consultant of CMC at Parexel Consulting. From 2005–2011, she was a Pharmaceutical Assessor at MHRA in London in the biologics/biotechnology unit and provided national and EU scientific advice for Advance Therapy Medicinal Products (ATMPs) for cell and gene therapy.

Ongoing engagements: Member of the Board, Idogen AB; May 2020 – present day

Experience: Margareth Jorvid has over 30 years’ experience in Regulatory Affairs for pharmaceuticals and has worked at the Medical Products Agency (MPA), as well as in large and small pharmaceutical companies such as Roussel Nordiska, Hoechst Marion Roussel (Stockholm and Paris, France) and Neopharma. Since 2006, consultant in regulatory affairs and quality assurance for pharmaceuticals and medical devices, as CEO of Methra Uppsala AB, LSM group. She is a Fellow and Honorary Life Member of TOPRA (The Organisation for Professionals in Regulatory Affairs), board member and TOPRA President 2005-2006.

Ongoing engagements: –

Past engagements during the last five (5) years: –